by telrheum | Dec 3, 2024 | Connective Tissue Diease, Anti-Synthetase Syndrome, Interstitial Lung Disease, Systemic Sclerosis
The “Classification Criteria for Anti-Synthetase Syndrome (CLASS) Project” sought to develop new, standardized guidelines to diagnose Anti-Synthetase Syndrome (ASSD), a rare autoimmune condition that primarily affects muscles, joints, and lungs and is linked to...
by telrheum | Aug 9, 2024 | Autoimmune Diseases, Connective Tissue Diease, Interstitial Lung Disease, Rheumatoid Arthritis, Sjögren’s Syndrome, Systemic Sclerosis
This study focuses on a treatment for patients with connective tissue diseases (CTD) who also have a lung condition called interstitial lung disease (ILD). This condition, when it becomes progressive and fibrosing (PF-ILD), can lead to serious lung damage. The...
by telrheum | Jun 15, 2024 | Systemic Sclerosis, Autoimmune Diseases, Calcinosis
Background: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases that primarily affect the muscles, causing inflammation. Calcinosis cutis, a condition where calcium deposits form in the skin, often accompanies connective tissue diseases, leading to...
by telrheum | May 27, 2024 | Sjögren’s Syndrome, Systemic Sclerosis
Study Background: This research focuses on finding reliable blood biomarkers to diagnose Interstitial Lung Disease (ILD) in patients with autoimmune diseases, specifically rheumatoid arthritis (RA) and systemic sclerosis (SSc). ILD is a serious complication in these...
by telrheum | May 25, 2024 | Interstitial Lung Disease, JAK Inhibitor, Systemic Sclerosis
This study explored the effectiveness and safety of nintedanib (NTB), a drug approved for progressive fibrosing interstitial lung disease (PF-ILD), in combination with immunosuppressive agents (IS) for treating connective tissue disease-associated PF-ILD (CTD-PF-ILD)....
by telrheum | Mar 30, 2024 | Biologic Therapy, Systemic Sclerosis
The article reports on a study where three patients with severe diffuse Systemic Sclerosis (SSc), a form of autoimmune disease, underwent a treatment involving CD19-targeting CAR-T cells. These cells are a type of therapy that modifies the patient’s T-cells to attack...
